


Lersivirine

ALTERNATE NAME: 5-[[3,5-diethyl-1-(2-hydroxyethyl)-1H-pyrazol-4-yl]oxy]-1,3-benzenedicarbonitrile

UK-453,061

CATALOG #:B3305-5 5 mg
B3305-25 25 mg

STRUCTURE:



MOLECULAR WEIGHT: 310.35

CAS NUMBER: 473921-12-9

APPEARANCE: Off-white to yellow to light brown powder

PURITY: ≥98%

SOLUBILITY: ~30 mg/ml DMSO

DESCRIPTION: Lersivirine is a non-nucleoside, next generation reverse transcriptase inhibitor ($IC_{50} = 118 \text{ nM}$ for the

wild-type HIV-1 enzyme). It inhibits a panel of 14 single-point mutant HIV-1 reverse transcriptases with mean IC $_{50}$ values within 10-fold of the wild-type enzyme. Lersivirine inhibits HIV-1 virus replication in MT-2 cells with EC $_{50}$ values of 5.04, 13.1, and 34.9 nM at multiplicities of infection (MOIs) of 0.005, 0.05, and 0.5, respectively, and displays synergistic or additive effects when used in combination with a

variety of antiretroviral agents.

STORAGE TEMPERATURE: -20°C. Protect from light

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of

exposure.

RELATED PRODUCTS:

Tenofovir disoproxil fumarate (1920) Abacavir hemisulfate (B2707) Stavudine (B2084) Azidothymidine (B1113)

DISCLAIMER: FOR RESEARCH USE ONLY! Not to be used on humans.